Compare CC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CC | MESO |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.1B |
| IPO Year | 2014 | 2005 |
| Metric | CC | MESO |
|---|---|---|
| Price | $15.66 | $17.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $20.11 | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 180.5K |
| Earning Date | 05-05-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,638,000,000.00 | N/A |
| Revenue This Year | $6.15 | $629.74 |
| Revenue Next Year | $5.95 | $30.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.36 | N/A |
| 52 Week Low | $10.44 | $12.66 |
| 52 Week High | $28.67 | $21.50 |
| Indicator | CC | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 59.57 |
| Support Level | $14.45 | $17.69 |
| Resistance Level | $16.44 | $19.53 |
| Average True Range (ATR) | 0.58 | 0.45 |
| MACD | 0.18 | 0.11 |
| Stochastic Oscillator | 71.82 | 80.20 |
The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, paints and coatings, plastics, transportation, semiconductor, and others. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.